What is Deepverge?
Founded in 2016 and headquartered in Malahide, Ireland, Deepverge operates as a vertically integrated entity that bridges physical laboratory testing with cloud-based analytical insights. The company's core value proposition centers on its Labskin platform, a sophisticated testing environment designed to scientifically validate product claims for the cosmetics, pharmaceutical, and clinical research industries. By leveraging artificial intelligence to detect and analyze bacterial interactions, Deepverge provides essential data-driven services that help enterprises navigate complex regulatory and consumer-facing landscapes. Its dual focus on environmental water monitoring and dermatological research positions the firm as a critical infrastructure provider in the life sciences sector.
How much funding has Deepverge raised?
Deepverge has raised a total of $14.2M across 1 funding round:
Share Placement
$14.2M
Share Placement (2021): $14.2M, investors not publicly disclosed
Key Investors in Deepverge
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Deepverge?
With this recent capital, Deepverge is expected to prioritize the expansion of its AI test services, specifically targeting increased market penetration in the global healthcare and water quality monitoring markets. The strategic roadmap likely involves enhancing the scalability of the Labskin platform to accommodate higher throughput for pharmaceutical clients while simultaneously refining its cloud-based diagnostic tools. As the company moves beyond its initial development phase, the focus will shift toward operational efficiency and the global deployment of its proprietary technology, ensuring that its AI-driven solutions remain at the forefront of industrial and clinical testing standards.
See full Deepverge company page
